Guardian Pharmacy Services, Inc. Class A (GRDN) AI Stock Analysis

34 Followers

Guardian Pharmacy Services, Inc. Class A

(NYSE:GRDN)

Select Model

Rating:74Outperform

Price Target:$44.00▲(4.54% Upside)

Action:upgraded

Date:09/11/26

GRDN scores well on improving fundamentals—rapid revenue growth, a sharp earnings rebound, and a notably de-risked balance sheet—supported by positive guidance revisions. The main constraints on the score are the premium valuation (high P/E with no dividend support) and technical indicators showing extended momentum, plus ongoing IRA reimbursement headwinds that may pressure reported revenue in the back half.

Positive Factors

Revenue and EBITDA GrowthRaised guidance, 23% first-half adjusted EBITDA growth, and strong underlying revenue before IRA effects indicate improving operating execution. Sustained growth can expand earnings capacity, support reinvestment, and strengthen Guardian’s position across its LTC pharmacy network over the next several quarters.

Negative Factors

IRA Reimbursement HeadwindsIRA pricing reductions are converting otherwise stronger underlying demand into weak or declining reported revenue. Continued reimbursement pressure can constrain top-line growth, complicate planning, and reduce the financial benefit of prescription and resident expansion until pricing effects are absorbed.

Guardian Pharmacy Services, Inc. Class A (GRDN) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $2.67B
Dividend Yield: ―
Average Volume (3M): 509.35K
Price to Earnings (P/E): 40.1
Beta (1Y): 0.55
Revenue Growth: 10.31%
EPS Growth: ―
Country: US
Employees: 3,600
Sector: General
Sector Strength: 55
Industry: Medical - Care Facilities

Guardian Pharmacy Services, Inc. Class A Business Overview & Revenue Model

Company Description

Guardian Pharmacy Services, Inc. operates as a pharmaceutical service provider, delivering an extensive array of tech-driven solutions. These services are specifically crafted to enhance the care of residents within long-term health care facilities (...

Guardian Pharmacy Services, Inc. Class A Earnings Call Summary

Earnings Call Date:Aug 05, 2026(Q2-2026)|% Change Since:6.64%|Next Earnings Date:Nov 04, 2026

Earnings Call SentimentPositive

The call reflected a positive operational and financial trajectory: strong adjusted EBITDA growth (23% YTD; 19% Q/Q), improved gross profit (+18% YoY), raised full-year guidance, robust clinical impact and disciplined capital allocation with nearly $90M cash and active M&A/greenfield expansion. Offsetting these positives are clear reimbursement headwinds from IRA pricing reductions that materially depressed reported revenue (Q2 +2%) and are expected to cause low single-digit reported declines in H2, continued margin dilution from ramping acquisitions/greenfields (though improving), and some cost pressures (fuel). Management emphasized mitigation actions, internal succession and disciplined deployment of capital, leaving the outlook upgraded but with ongoing uncertainty tied to future IRA tranches and integration ramps.

Positive Updates

Raised Full-Year Guidance

Company raised 2026 revenue guidance to $1.43B–$1.45B (from $1.40B–$1.42B) and adjusted EBITDA to $129M–$131M (from $123M–$127M), reflecting confidence based on year-to-date performance.

Negative Updates

IRA-Related Pricing Reductions Pressuring Reported Revenue

IRA-related pricing changes materially reduced reported revenue growth: reported revenue was only +2% YoY in Q2 but would have been low double-digits absent IRA. Management expects reported revenue to decline low single-digits YoY in the second half of 2026 due to continued IRA impact.

Company Guidance

Guardian raised full‑year 2026 guidance to revenue of $1.43–$1.45 billion (previously $1.40–$1.42B) and adjusted EBITDA of $129–$131 million (previously $123–$127M), reflecting strong YTD execution including H1 reported revenue +2% (would have been low‑double‑digit growth absent IRA pricing) and adjusted EBITDA growth of 23% in H1; Q2 results included revenue of $351.2M (+2% YoY), gross profit $80M (gross margin 22.8%), SG&A $56.5M (16.9% of revenue), adjusted EBITDA $29.7M (+19% YoY, 8.4% margin), net income $22.1M (includes an $8.5M settlement excluded from adj. EBITDA), residents served >210,000 (scripts up high single‑digits), cash ≈$90M (vs. ~$65M prior quarter), stock‑based comp ~$2.9M/quarter and an effective tax rate of 26%; management expects second‑half reported revenue to decline low‑single‑digits YoY due to IRA pricing (absent IRA underlying growth would be high‑single‑digits), adj. EBITDA margin roughly stable in Q3 with a seasonal Q4 pickup, the 2027 IRA tranche is ~40% of 2026’s, and guidance excludes any contribution from future acquisitions.

Guardian Pharmacy Services, Inc. Class A Financial Statement Overview

Summary

Financials are improving meaningfully: strong revenue growth (~51% TTM) with a rebound to positive operating profit and net income, a much stronger balance sheet with very low leverage (debt-to-equity ~0.03), and solid positive free cash flow. Offsets include prior profitability volatility (notably 2024) and somewhat uneven cash conversion versus accounting earnings.

Income Statement

78Positive

Balance Sheet

86Very Positive

Cash Flow

74Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.46B	1.45B	1.23B	1.05B	908.91M	792.07M
Gross Profit	316.58M	282.04M	244.37M	208.31M	185.87M	161.26M
EBITDA	119.81M	96.42M	-43.43M	58.81M	68.15M	46.49M
Net Income	65.91M	49.22M	-87.29M	23.90M	35.42M	16.31M
Balance Sheet
Total Assets	443.58M	412.66M	320.81M	271.17M	256.11M	235.85M
Cash, Cash Equivalents and Short-Term Investments	89.81M	65.62M	4.66M	752.00K	607.00K	15.01M
Total Debt	35.24M	37.14M	30.13M	69.15M	62.98M	55.04M
Total Liabilities	185.94M	194.73M	170.83M	211.31M	180.18M	182.53M
Stockholders Equity	245.61M	205.76M	142.67M	28.21M	42.73M	23.93M
Cash Flow
Free Cash Flow	79.78M	80.71M	41.59M	56.26M	31.75M	49.22M
Operating Cash Flow	98.86M	100.29M	57.96M	70.82M	48.52M	58.50M
Investing Cash Flow	-22.73M	-32.26M	-30.41M	-13.44M	-17.90M	-13.15M
Financing Cash Flow	-5.13M	-7.07M	-23.64M	-57.23M	-45.03M	-36.79M

Guardian Pharmacy Services, Inc. Class A Technical Analysis

Technical Analysis SentimentPositive

Last Price42.09

Price Trends

50DMA41.25Positive

100DMA40.77Positive

200DMA38.27Positive

Market Momentum

MACD-0.11Negative

RSI57.31Neutral

STOCH64.34Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRDN, the sentiment is Positive. The current price of 42.09 is above the 20-day moving average (MA) of 40.30, above the 50-day MA of 41.25, and above the 200-day MA of 38.27, indicating a bullish trend. The MACD of -0.11 indicates Negative momentum. The RSI at 57.31 is Neutral, neither overbought nor oversold. The STOCH value of 64.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GRDN.

Guardian Pharmacy Services, Inc. Class A Risk Analysis

Guardian Pharmacy Services, Inc. Class A disclosed 42 risk factors in its most recent earnings report. Guardian Pharmacy Services, Inc. Class A reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Guardian Pharmacy Services, Inc. Class A Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

GRDN against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NHC	81Outperform	$3.22B	23.52	12.94%	1.23%	7.19%	32.91%
ENSG	75Outperform	$10.63B	27.25	16.63%	0.14%	17.49%	19.82%
GRDN	74Outperform	$2.59B	40.09	30.80%	―	10.31%	―
OPCH	72Outperform	$4.76B	22.77	16.36%	―	5.95%	5.33%
PACS	70Outperform	$7.39B	28.72	25.77%	―	11.02%	62.56%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
BKD	48Neutral	$2.48B	-19.33	405.63%	―	-4.42%	44.67%

* General Sector Average

Performance Comparison

GRDN and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GRDN	Guardian Pharmacy Services, Inc. Class A	42.09	13.60	47.74%
OPCH	Option Care Health Inc	31.65	4.61	17.05%
BKD	Brookdale Senior Living Inc.	11.19	2.08	22.83%
NHC	National Healthcare	212.40	89.24	72.46%
ENSG	The Ensign	188.31	5.67	3.10%
PACS	PACS Group Inc	50.26	37.78	302.72%

Guardian Pharmacy Services, Inc. Class A Corporate Events

Business Operations and StrategyRegulatory Filings and Compliance

Guardian Pharmacy Implements Insider Lock-Up to Support Stability

Positive

Sep 10, 2026

Guardian Pharmacy Services, Inc. entered into lock-up agreements on September 10, 2026 with its founders, executive officers and certain employees covering approximately 29.9 million shares of Class A common stock. These shares represent about 81% of...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 11, 2026

Guardian Pharmacy Services, Inc. Class A AI Stock Analysis